GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sonnet BioTherapeutics Holdings Inc (NAS:SONN) » Definitions » Total Current Liabilities

Sonnet BioTherapeutics Holdings (Sonnet BioTherapeutics Holdings) Total Current Liabilities : $2.77 Mil (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Sonnet BioTherapeutics Holdings Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Sonnet BioTherapeutics Holdings's total current liabilities for the quarter that ended in Mar. 2024 was $2.77

Sonnet BioTherapeutics Holdings Total Current Liabilities Historical Data

The historical data trend for Sonnet BioTherapeutics Holdings's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sonnet BioTherapeutics Holdings Total Current Liabilities Chart

Sonnet BioTherapeutics Holdings Annual Data
Trend Sep19 Sep20 Sep21 Sep22 Sep23
Total Current Liabilities
2.89 4.72 6.70 8.17 5.53

Sonnet BioTherapeutics Holdings Quarterly Data
Sep19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.77 6.47 5.53 2.65 2.77

Sonnet BioTherapeutics Holdings Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Sonnet BioTherapeutics Holdings's Total Current Liabilities for the fiscal year that ended in Sep. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=3.339+0.073
+Other Current Liabilities+Current Deferred Liabilities
=2.094+0.019
=5.53

Sonnet BioTherapeutics Holdings's Total Current Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=2.556+0.078
+Other Current Liabilities+Current Deferred Liabilities
=0.131+0
=2.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Sonnet BioTherapeutics Holdings Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Sonnet BioTherapeutics Holdings's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Sonnet BioTherapeutics Holdings (Sonnet BioTherapeutics Holdings) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sonnet BioTherapeutics Holdings Inc (NAS:SONN) » Definitions » Total Current Liabilities
Comparable Companies
PKBO GSTC PBLA ADIL ALLR SCPS ARTH AMPE DRMA CDIO OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
100 Overlook Center, Suite 102, Princeton, NJ, USA, 08540
Website
https://www.sonnetbio.com
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
Executives
John Markey 10 percent owner 10096 RIDGEWOOD DRIVE, TWINSBURG OH 44087
Susan Dexter officer: Chief Technical Officer C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Albert D. Dyrness director C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Nailesh Bhatt director C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Pankaj Mohan director, officer: Chairman, President and CEO C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Lori Mcneill director C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, SUITE 102, PRINCETON NJ 08540
Richard T Kenney officer: Chief Medical Officer C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102
Donald J. Griffith director C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Terence Anthony Rugg officer: Chief Medical Officer C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
John K. Cini officer: Chief Scientific Officer C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Raghu Rao director C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Cross John Harry Iii officer: Chief Financial Officer C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Oz Rey Llc 10 percent owner 918 CONGRESS AVENUE, SUITE 100, AUSTIN TX 78701
Mv Amanth Llc 10 percent owner 515 CONGRESS AVE, STE 1400, AUSTIN TX 78701-3516
Robert Sumner Hersch 10 percent owner 515 CONGRESS AVE, STE 1400, AUSTIN TX 78701